Albuminuria Clinical Trial
Official title:
Randomized Cross-over Study Examining the Effects of Phosphorus Additives on Urinary Albumin Excretion and Fibroblast Growth Factor-23
Phosphorus-based food additives are commonly used by food manufacturers for many
applications, such as enhancing flavor, in ready-to-eat foods and beverages. While these
additives can significantly increase an individual's daily phosphorus intake, little is known
about the effect of dietary phosphorus on kidney health. In this study, the investigators
will first lower baseline phosphorus intake to about 1000mg/d by educating participants to
avoid foods with phosphorus additives. Then, participants will be randomized to a higher
phosphorus period (~2gm/d) and a lower phosphorus period (~1gm/d) by providing unaltered,
commercially-available food/beverage products with and without phosphorus additives.
The investigators hypothesize that participants will have higher urine albumin excretion and
fibroblast growth factor-23 (FGF-23) during the higher phosphorus period compared to the
lower phosphorus period.
The Study of Dietary Additive Phosphorus on Proteinuria and FGF-23 (SODA-POP) was a single-center, randomized, double-blind, two-period cross-over study that examined the effect of higher vs. lower phosphorus intake for 3 week periods, achieved by addition of commercially available diet beverages and breakfast bars to diet on albuminuria and fibroblast growth factor 23, in adults with presumed early chronic kidney disease (estimated glomerular filtration rate >= 45 ml/min/1.73m2; and urine albumin/creatinine ratio >=17 mg/g for men or >=25 mg/g for women). ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT00095290 -
Irbesartan Versus Placebo in Combination With Ramipril for Treatment of Albuminuria
|
Phase 4 | |
Completed |
NCT02144740 -
Effect of NWT-03 on Blood Pressure
|
N/A | |
Completed |
NCT01041599 -
Correlation of Albuminuria With Arterial Stiffness
|
N/A | |
Active, not recruiting |
NCT05321095 -
Screening for Albuminuria at the First Line for Early Identification of CKD
|
||
Completed |
NCT02945969 -
Sodium Lowering and Urinary Protein Reduction Trial
|
Phase 3 | |
Enrolling by invitation |
NCT04295889 -
Towards HOMe-based Albuminuria Screening: an Implementation Study Testing Two Approaches
|
N/A | |
Recruiting |
NCT04272359 -
Substitution of Sulfonylureas With New Generation of Hypoglycemic Drugs for the Treatment of Type 2 Diabetes Mellitus
|
||
Completed |
NCT03889236 -
Dietary Interventions on Glycocalyx Dimensions in South Asian Patients With Diabetic Nephropathy.
|
N/A | |
Active, not recruiting |
NCT00625820 -
Tetrahydrobiopterin in Patients With Chronic Kidney Disease (CKD) and Albuminuria
|
Phase 2 | |
Recruiting |
NCT04752293 -
Pediatric Hypertension and the Renin-Angiotensin SystEm (PHRASE)
|
||
Completed |
NCT03118739 -
Intensive Uric Acid Lowering With Verinurad and Febuxostat in Patients With Albuminuria
|
Phase 2 | |
Completed |
NCT06374043 -
Decentralized N=1 Study: A Feasible Approach to Evaluate Individual Therapy Response to Dapagliflozin.
|
Phase 4 | |
Completed |
NCT03396328 -
Effects of Intensive Low-Salt Diet Education by Mobile Application on Albuminuria
|
N/A | |
Not yet recruiting |
NCT06094920 -
Treatment Optimization for Patients With Type 2 Diabetes Using Empagliflozin and Finerenone in a Remote Clinical Trial
|
Phase 4 | |
Recruiting |
NCT00342927 -
Family Investigation of Nephropathy and Diabetes (F.I.N.D.)
|
||
Completed |
NCT02689778 -
Effect of Pirfenidone on Glomerular Filtration Rate and Albuminuria in Patients With Diabetic Nephropathy
|
Phase 3 | |
Completed |
NCT02497300 -
Vascular Effects of Mineralocorticoid Receptor Antagonism in Kidney Disease
|
Phase 2 | |
Completed |
NCT02446548 -
Influence of Aliskiren on Albuminuria After Kidney Transplantation
|
N/A | |
Completed |
NCT01547897 -
NOX-E36 in Patients With Type 2 Diabetes Mellitus and Albuminuria
|
Phase 2 | |
Enrolling by invitation |
NCT01316068 -
Effect of Sulodexide on Albuminuria in Chinese Type 2 Diabetic Patients
|
Phase 4 |